Abstract
Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge.
Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.Keywords: PI3K/Akt/mTOR, breast cancer, cell proliferation, intracellular, cytotoxic, therapy.
Current Pharmaceutical Design
Title:PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation
Volume: 23 Issue: 11
Author(s): Var Ruchi Sharma, Girish Kumar Gupta, A. K. Sharma, Navneet Batra, Daljit K. Sharma, Amit Joshi and Anil K. Sharma*
Affiliation:
- Department of Biotechnology, M.M. University, Mullana-Ambala -133207, Haryana,India
Keywords: PI3K/Akt/mTOR, breast cancer, cell proliferation, intracellular, cytotoxic, therapy.
Abstract: Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge.
Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.Export Options
About this article
Cite this article as:
Sharma Ruchi Var, Gupta Kumar Girish, Sharma K. A., Batra Navneet, Sharma K. Daljit, Joshi Amit and Sharma K. Anil*, PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612823666161116125218
DOI https://dx.doi.org/10.2174/1381612823666161116125218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophins' Modulation by Olive Polyphenols
Current Medicinal Chemistry Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Necroptosis: Who Knew There were so Many Interesting Ways to Die?
CNS & Neurological Disorders - Drug Targets Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot topic: In Vitro Imaging (Guest Editors: Flora Tang and Jinghai J. Xu)]
Combinatorial Chemistry & High Throughput Screening Para-Nonylphenol Induces Apoptosis of U937 Human Monocyte Leukemia Cells in vitro
Endocrine, Metabolic & Immune Disorders - Drug Targets Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Editorial: Herbal Medicine on High Impact Disease: The Current Progress and Application
Current Pharmaceutical Design Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Vitamin D Represses the Aggressive Potential of Osteosarcoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment of Estrogen-Dependent Breast Cancer
Current Medicinal Chemistry Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
Current Cancer Therapy Reviews Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Breast Cancer and Flavonoids - A Role in Prevention
Current Pharmaceutical Design Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets